Clinical Study And Literature Review Of 35 Patients With Therapy-related Hematological Neoplasms

Objective The purpose of this study was to explore the clinical characteristics,treatment and prognosis of patients with therapy-related hematological neoplasms,so as to improve the understanding of the therapy-related hematological neoplasms.Methods 35 therapy-related hematological neoplasms patients who from May 2006 to February 2020 in General Hospital of Ningxia Medical University were retrospectively enrolled in this study.Discussing the previous disease,treatment and laboratory data with literature retrieval.Results The median age of 35 patients with therapy-related hematological neoplasms was 57(24~78)years,of which 33(94.3%)had the first disease as solid tumor,and 2(5.7%)had the first disease as rheumatic disease.The median time(median latency)between initial disease treatment and the onset of therapy-related hematological neoplasms was 48(1~246)months.Among them,25 cases are therapy-related acute myeloid leukemia(t-AML),with a median onset interval of 48(7~164)months.3 cases are therapy-related acute lymphoblastic leukemia(t-ALL)with a median interval of 13(1-30)months.5 cases are therapy-related nonHodgkin lymphoma(t-NHL),with a median interval of 80(36~246)months.There is 1 case of t-CMML and 1 case of t-MPN.The median survival time of 28 patients with therapyrelated acute leukemia(t-AL)was 7.5 months(1-102 months),the 1-year cumulative survival rate is 41.7%,the 2-year cumulative survival rate is 15.6%,and the 3-yearcumulative survival rate is 7.8%.Chemotherapy and achieving complete remission(CR)in first course were beneficial to prolong the survival of t-AL patients.Conclusion Therapy-related hematological neoplasms are heterogeneous diseases and have a poor prognosis,so it should be treated accurately based on clinical manifestations and cytogenetic characteristics.